目的 觀察注射用丹參多酚酸對急性期缺血性腦卒中患者的臨床療效及安全性。方法 選取2018年6月—2019年6月保定市第一中心醫(yī)院收治的100例急性期缺血性腦卒中住院患者，隨機(jī)分為常規(guī)藥物治療組（對照組）和注射用丹參多酚酸治療組（試驗組），各50例。對照組給予常規(guī)治療，試驗組在對照組基礎(chǔ)上加用注射用丹參多酚酸0.13 g溶于250 mL0.9%氯化鈉注射液中，靜脈滴注、每天1次，兩組均連續(xù)治療2周。觀察兩組臨床療效，分別檢測治療前和治療2周后兩組患者血清細(xì)胞間黏附分子-1（ICAM-1）及腫瘤壞死因子-α（TNF-α）水平，并對患者進(jìn)行美國國立衛(wèi)生研究院卒中量表（NIHSS）評分及日常生活能力評定量表（BI）評分。結(jié)果 兩組治療前NIHSS評分、BI評分及血清ICAM-1、TNF-α水平無明顯差異；治療后兩組NIHSS評分及血清ICAM-1、TNF-α水平均較同組治療前降低，且試驗組顯著低于對照組（P＜0.05），兩組BI評分均較治療前升高，且試驗組BI評分較對照組顯著升高（P＜0.05）；治療后，對照組總有效率66.0%，試驗組總有效率88.0%，兩組比較差異顯著（P＜0.05）。兩組均未出現(xiàn)不良反應(yīng)。結(jié)論 注射用丹參多酚酸可改善急性期缺血性腦卒中患者神經(jīng)功能，可有效降低患者血清ICAM-1及TNF-α水平。

Objective To observe the clinical efficacy and safety of Salvianolic Acids for Injection (SAFI) in patients with acute cerebral infarction. Methods A total of 100 patients with acute cerebral ischemic stroke admitted to the Baoding NO. 1 Central Hospital from June 2018 to June 2019 were selected and randomly divided into conventional drug treatment group (control group) and SAFI treatment group (experimental group) with 50 cases each by using random number table. The control group was given conventional drugs for cerebral ischemic stroke, and the experimental group was additionally given 0.13 g SAFI dissolved in 250 mL 0.9% Sodium Chloride Injection, intravenously once a day, and both groups were given consecutive two weeks. Observe the clinical efficacy of two groups, serum levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor-α (TNF-α) were detected before and two weeks after treatment, and the patients were evaluated by the National Institutes of Health Stroke Scale (NIHSS) score and the Ability to Daily Living Scale (BI) score. Results There were no significant differences in NIHSS scores, BI scores and serum levels of ICAM-1 and TNF-α expression between control group and experimental group before treatment. After treatment, NIHSS scores and serum levels of ICAM-1 and TNF-α were decreased in both groups, and the experimental group was significantly lower than the control group (P＜0.05). BI scores in both groups were increased, and BI scores in the experimental group were significantly higher than those in the control group (P＜0.05). The total effective rate of the control group was 66.0%, while the total effective rate of the experimental group was 88.0%, there was a significant difference between two groups (P＜0.05). There were no adverse reactions in two groups. Conclusion SAFI can improve the neurological function of patients with acute cerebral ischemic stroke, and can effectively reduce the levels of serum ICAM-1 and TNF-α.

R286.1，R971

河北省衛(wèi)生廳重點(diǎn)研究項目（20181487）